Rentschler Biopharma, a Germany-based biopharmaceuticals manufacturer with a facility in Milford, is set to produce a novel ...

Contract development and manufacturing organization (CDMO) Rentschler Biopharma has announced a partnership with ...

The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to ...

In clinical laboratory settings, coagulation factor tests are routinely conducted to identify inherited or acquired deficiencies in patients suspected of an ongoing bleeding risk. These tests ...

For India, the future is likely a hybrid ecosystem: robust central laboratory analyzers complemented by decentralised, rapid-response coagulation devices. Sysmex is well positioned to operate across ...

CORRECTION of abnormally low concentration of plasma components is usually attempted by replacement therapy. However, evidence from studies of purpura fulminans in man 1,2 and from studies of the ...

The compendium of newly emerging and currently available hemophilia and anticoagulant treatments, while offering new choices for improved patient care, can create significant levels of interference ...

Researchers used a technique in genetic analysis termed Mendelian randomization to examine 12 coagulation measures, uncovering four that are associated with migraine susceptibility. Nearly 15 percent ...

DIC can be acute or chronic in nature. Chronic DIC is generally seen in the cancer population and is demonstrated as localized thrombotic events (eg, deep vein thromboses). Chronic DIC is defined as a ...

Patients with cancer are more likely to die from cardiovascular diseases, according to a study. The study, published in the ...